Jazz Builds Real-World Case for Zanidatamab in Advanced HER2+ Gastroesophageal Cancer
TipRanks (Fri, 2-Oct 12:30 PM ET)
Nuvation, Jazz gain new Buys at Citi on oncology prospects
Seeking Alpha News (Wed, 30-Sep 1:47 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
TipRanks (Mon, 28-Sep 7:00 AM ET)
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
PRNewswire (Tue, 15-Sep 9:01 AM ET)
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 2-Sep 4:15 PM ET)
PRNewswire (Mon, 31-Aug 6:00 AM ET)
PRNewswire (Thu, 27-Aug 12:31 AM ET)
PRNewswire (Wed, 26-Aug 7:00 AM ET)
PRNewswire (Tue, 25-Aug 10:02 AM ET)
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
PRNewswire (Mon, 10-Aug 7:30 AM ET)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals PLC - trades on the NASDAQ stock market under the symbol JAZZ.
As of October 2, 2026, JAZZ stock price climbed to $235.67 with 506,606 million shares trading.
JAZZ has a beta of 0.11, meaning it tends to be less sensitive to market movements. JAZZ has a correlation of 0.00 to the broad based SPY ETF.
JAZZ has a market cap of $14.79 billion. This is considered a Large Cap stock.
Last quarter Jazz Pharmaceuticals PLC - reported $1 billion in Revenue and $5.71 earnings per share. This beat revenue expectation by $100 million and missed earnings estimates by -$.23.
In the last 3 years, JAZZ traded as high as $266.38 and as low as $95.49.
The top ETF exchange traded funds that JAZZ belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
JAZZ has outperformed the market in the last year with a return of +72.1%, while the SPY ETF gained +16.3%. However, in the most recent history, JAZZ shares have underperformed the stock market with its stock returning -0.8% in the last 3 month period and -3.4% for the last 2 week period, while SPY has returned +3.5% and +1.4%, respectively.
JAZZ support price is $229.43 and resistance is $236.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAZZ shares will trade within this expected range on the day.
